Although the 2020 American College of Rheumatology guidelines for gout management released in May 2020 are an improvement over the 2012 guidelines, gaps in disease management remain, according to a presentation at the 2020 Congress of Clinical Rheumatology-East.
During the session, “The 2020 ACR Gout Management Guidelines. What’s New. What’s Missing,” presenter N. Lawrence Edwards, MD, said the management of gout remains poor, despite strong recommendations from the guidelines addressing standard treat-to-target urate lowering therapy (ULT).
Dr Edwards said he thought the 2020 guidelines were missing tools to assess the risk of cardiovascular disease and chronic kidney diseases linked with allopurinol. Patients with cardiovascular disease are at an increased risk of hypersensitivity to allopurinol.
Edwards NL. The 2020 ACR Gout Management Guidelines. What’s New. What’s Missing. Presented at: Congress of Clinical Rheumatology-East annual symposium (Virtual).